Is the Risk of Infection Higher During Treatment with Secukinumab than with TNF-inhibitors? An Observational Study from the Nordic Countries
Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac358
Glintborg B et al, highlight in their recent research from the Nordic countries, that there is a low frequency of hospitalised infections during treatment with secukinumab or TNFi in patients with SpA and PsA. In clinical practice, secukinumab was found to double absolute risk of 1st year hospitalised infection compared with adalimumab, with the other TNFi treatments falling in between.
Risque d‘Infection Grave chez les Patients Atteints de Polyarthrite Rhumatoïde en Soins Courants avec Abatacept, Rituximab et Tocilizumab au Danemark et en Suède
Ann Rheum Dis. 2019 Mar;78(3):320-327. DOI: 10.1136/annrheumdis-2018-214326Differences in baseline characteristics and numerical differences in IR of SI between ABA, RRTX and TOZ were observed. The relative risk (RR) of SIs seemed to vary modestly with drug.TNFi treated RA patients in large observational studies have suggested an initial twofold increased risk of SIs compared with biologic-naïve patients. Long-term observational studies on the risk of SIs in patients treated with non-TNFi bDMARDs are sparse.This study aimed to estimate crude as well as age and gender-a...